Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA Animal Free,Azide Free,Carrier Free,ExactAb™,Low Endotoxin,Recombinant,Validated for sensitive chromatographic and analytical workflows requiring minimal baseline interference.
Store at -80°C,Avoid repeated freezing and thawing Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.
SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.
Cited in 1 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.
Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research.
Purity
>95% (SDS-PAGE&SEC)
Endotoxin Level
< 1.0EU/mg
Siltuximab (anti-IL-6) (Ab169289)- ELISA
Immobilized Recombinant Human IL-6 Protein (rp147615) at 1 μg/mL can bind Siltuximab (anti-IL-6) (Ab169289) with the EC₅₀ of 47.28 ng/mL.
Siltuximab (anti-IL-6) (Ab169289) - SEC
The purity of Siltuximab (anti-IL-6) (Ab169289) is more than 95% verified by HPLC.
Comprehensive hazard, handling, storage, and regulatory compliance document.
Download SDS →Lot-specific quality data. Enter your lot number to retrieve the exact COA.
Look up COA →Full quality attributes and acceptance criteria for this grade.
View spec sheet →| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
| Lot Number | Certificate Type | Fecha | Articulo |
|---|---|---|---|
 ZJ24F0809665 | Certificate of Analysis | Jun 22, 2026 | Ab169289 |
| ZJ24F0809666 | Certificate of Analysis | Jun 22, 2026 | Ab169289 |
| ZJ24F0809667 | Certificate of Analysis | Jun 22, 2026 | Ab169289 |
| ZJ23F0900978 | Certificate of Analysis | Jun 24, 2025 | Ab169289 |
| ZJ23F0900979 | Certificate of Analysis | Jun 24, 2025 | Ab169289 |
| ZJ26F0636100 | Certificate of Analysis | Jun 24, 2025 | Ab169289 |
| 1. Ding Ma, Yi Xu, Long Chen, Yaojun Wang, Chang Chen, Dongchen Zhu, Yijun Cao, Mei Tian, Yidan Gao, Xianqiang Mi. (2026) Lung Cancer Cell–Macrophage Interaction System for Signal Pathway-Based Logic Analysis and Drug Testing. ACS Nano, [PMID:41540768] [10.1021/acsnano.5c18240] |
Our grade selection guide covers purity, stabilizer status, and application suitability for all variants in our catalog.
View Animal Free grade guide → View Carrier Free grade guide → View Recombinant grade guide → View Validated grade guide → View ExactAb™ grade guide → View Low Endotoxin grade guide → View Azide Free grade guide →
